Clinical studies involving oral administration of rosuvastatin (10 mg) combined with CB capsules (1200 mg daily) have shown significant reductions in levels of total bilirubin (TBIL), direct bilirubin (DBIL), ALT, AST, TC, TGs, free fatty acids (FFA), collagen III peptide (PIIIP), type IV collagen (C-IV), hyaluronic acid (HA), laminin (LN), TNF-α, C-reactive protein (CRP), and IL-6 among patients with NAFLD. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.